Correction to “Long‐Term Real‐World Survival of Immuno‐ therapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score‐Matched Analysis”

K. Kim, M. Sweeting, L. Jönsson, and N. Wilking, “Long‐Term Real‐World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score‐Matched Analysis,” Thoracic Cancer 16, no. 1 (2025): e15535.

Figure 2 has been corrected to include five data labels for “The second line therapy”.

Below is the correct Figure 2.

FIGURE 2.

Changes in treatment patterns for metastatic nonsmall cell lung cancer since the introduction of immuno‐oncology, in the first‐ and second‐line therapy. CT, chemotherapy; IO, immuno‐oncology; PBDC, platinum‐based doublet chemotherapy.